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area of active research that has witnessed unprecedented
change in recent years with the emergence of transarte-
rial chemoembolization (TACE) and sorafenib as palli-
ative standard of care, new potentially curative
treatments such as radiofrequency, and the consolida-
tion of an evidence-based approach to evaluate all
potential treatment options [1]. The implementation of
screening through biannual abdominal ultrasound [2]
has led to increased diagnosis of HCC at early stages
in more than 50% of correctly screened patients. How-
ever, despite the correct implementation of surveillance
programs, more than half of patients with HCC are
diagnosed late, when potential curative treatment can-
not be applied. In addition, in a high proportion of cases
the disease recurs after a radical therapy. Therefore,
despite signiﬁcant advancements, the development of
new therapeutic approaches or the reﬁnement of cur-
rently available treatments for non-early HCC has high
priority in the ﬁeld of clinical research in HCC.
It is well known that HCC is a neoplasm whose pro-
gression is strongly linked to neoangiogenic activity. In
contrast to the dual vascularization (portal and arterial)0168-8278/$36.00  2009 European Association for the Study of the Liver.
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drug eluting bead.typical of the liver parenchyma, HCC has a vascular
supply mostly dependent on the hepatic artery. This fea-
ture has constituted the pathophysiological rationale for
the development of several intra-arterial procedures. In
that sense, the intra-arterial administration of diﬀerent
drugs or devices allows its distribution almost exclu-
sively within the tumor, and the acute arterial obstruc-
tion of the feeding arteries results in selective ischemic
tumor necrosis. The techniques and agents used to treat
HCC by intra-arterial means are very heterogeneous
and could be schematically summarized as those that
only deliver an active agent into the tumor (transarterial
chemotherapy (TAI), or lipiodolization if this carrier is
used aiming to increase tumor exposure to the drug),
those that are only aimed at blocking the artery blood
ﬂow (transarterial embolization), and ﬁnally those that
consider both procedures (TACE and, more recently,
radioembolization).
Despite the wide use of these procedures since the late
80s, their beneﬁts were until recently questionable. Sev-
eral randomized-controlled trials (RCTs), mainly per-
formed in France, failed to show improvement in
survival, but two RCTs published in 2002, one con-
ducted in Barcelona [3] and the other in Hong Kong
[4], followed by a systematic meta-analysis [5] showed
that TACE has a signiﬁcant and positive impact on sur-
vival in well-selected patients with preserved liver func-
tion. The discrepancies between these trials could
result from diﬀerences in the main etiologies of chronic
liver diseases (alcohol in France, virus in Spain and
Japan) and subsequent alteration in liver function
(higher in alcoholic than in viral diseases) [6]. After these
successful clinical trials, the main scientiﬁc associationsPublished by Elsevier B.V. All rights reserved.
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the standard of care for intermediate HCC [2].
As we have commented before, TACE is not the only
locoregional, intra-arterial procedure. Some authors
argue that the real impact of these treatments relies on
the obstruction of the arterial blood ﬂow, and the addi-
tion of chemotherapy not only has no beneﬁt, but also
may increase the toxicity and the rate of side-eﬀects.
Disappointingly, few trials have been conducted to eval-
uate this issue and the survival advantage has been only
found with TACE but not with embolization alone.
Nevertheless, these results should be considered with
caution given the small sample size of the studies. In
contrast, other authors have suggested that the real eﬃ-
cacy of these locoregional procedures comes from the
intra-tumoral delivery of high doses of active agents,
and hence the addition of embolization could not
improve the eﬃcacy, and could even potentially aug-
ment the side-eﬀects and limit the applicability and ben-
eﬁts of these locoregional therapies.
With the aim of evaluating the real impact of adding
embolization on the overall survival of patients treated
with TAI, Okusaka and collaborators conducted a
multi-center, open-label trial to compare the eﬀects of
TACE and TAI and to clarify the possible beneﬁts of
treatment intensiﬁcation performing embolization with
gelatin-sponge particles in addition to infusion chemo-
therapy [7]. In this study, zinostatin stimalamer
(SMANCS), a lipophilic anticancer agent that dissolves
in lipiodol to form a stable solution, was selected as the
chemotherapeutic agent for use with both TACE and
TAI. The primary endpoint was survival from random-
ization, and the secondary endpoints were tumor
response and toxicity. A total of 161 patients were ran-
domly allocated to the TACE group (n = 79) or the TAI
group (n = 82). At the time of the ﬁnal analysis, 51
patients in the TACE group and 58 patients in the
TAI group had died, and the median overall survival
time was 646 days and 679 days, respectively
(p = 0.383). Regarding tumor response, the proportion
of patients with more than 50% of tumor necrosis
among the patients with measurable lesions was not sig-
niﬁcantly diﬀerent between the TACE group and the
TAI group (48.1% vs. 34.2%; p = 0.11). Therefore, the
results of this study suggest that treatment intensiﬁca-
tion by adding embolization did not increase the sur-
vival of HCC patients over SMANCS transarterial
chemotherapy alone [7].
Can it be inferred from these results that emboliza-
tion after intra-arterial chemotherapy does not improve
survival? The answer probably is no, and it is based on
several points that we will attempt to summarize. The
ﬁrst concern is the high rate of screening failures (61
out of 222 patients) because of ineligibility for intra-
arterial treatment based on angiographic ﬁndings. This
fact could reﬂect ill-deﬁned eligibility criteria, and subse-quently the patients’ inclusion may be based in part on
the investigator criteria. Undoubtedly, this strategy cer-
tainly allows the inclusion of a heterogeneous popula-
tion and in addition, constitutes a source for selection
bias. In particular, the proportion of patients with cir-
rhosis in each group was not reported. Second, this
RCT included patients with far-advanced tumors:
approximately 40% of cases are advanced HCC and
serum alpha-fetoprotein was >400 ng/mL in one-third.
In this population, transarterial locoregional therapies,
regardless of the methodology used, have poor impact
on survival. Third, there was not a pre-planned treat-
ment schedule, and after the ﬁrst procedure, the next
sessions were done according to the investigator criteria,
resulting again in a source of potential bias. In addition,
the number of protocol repetition treatments was very
low (median courses, 2.2–2.4), so we could hypothesize
that the maximum anticancer potential may have not
been achieved. The next issue concerns the assessment
of tumor response. This was done by CT scan one
month after the completion of treatment and every 3–4
months thereafter and considered lipiodol accumulation
in the tumor as an indicator of tumor necrosis.
Although the authors have justiﬁed the measurement
of lipiodol accumulation as a surrogate of necrosis with
previously published radiologic–pathologic correlation
studies, a more reliable strategy would have been to
use magnetic resonance imaging (MRI) that could have
allowed them to measure with conﬁdence the area of
necrosis. Finally, we would like to highlight the high rate
of side-eﬀects, which may be justiﬁed by the use of
SMANCS in both groups, and could impair the poten-
tial beneﬁt of these procedures and counteract any ben-
eﬁt from therapy.
Nonetheless, we should not lose sight of the accom-
plishment of the authors. RCTs in the ﬁeld of HCC
are diﬃcult to perform and are always very welcome.
Okusaka and collaborators should be commended for
having conducted a multi-center RCT aimed at answer-
ing this relevant question that fulﬁlls the criteria put for-
ward by the CONSORT statement (www.consort-
statement.org) [8]. Unfortunately this trial was con-
ducted between 1999 and 2003 and several break-
throughs in the ﬁeld of intra-arterial locoregional
therapies have been made in the meantime. One of the
most recent advancements has been the development
of the drug eluting beads (DEBs) that allow a slow
release of chemotherapy while simultaneously inducing
a calibrated arterial obstruction. Consequently, the use
of DEBs for TACE sharply decreases the passage of
drug to the systemic circulation, minimizing the appear-
ance of side-eﬀects associated to chemotherapy, and
could induce an outstanding rate of objective responses
[9–11]. With these encouraging preliminary results, the
current comparison between TACE using state-of-the-
art devices and TAI is unjustiﬁed from an ethical point
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conﬁrm (or not) the results presented by Okusaka and
collaborators.
Further advancements are needed in the ﬁeld of loco-
regional therapies in HCC. As emphasized by Okusaka
and collaborators, rapid evaluations of new techniques
using RCTs are diﬃcult to perform and signiﬁcant
improvements could result from pooling large prospec-
tive databases from diﬀerent geographical areas [6].
Eﬀorts should be directed to develop and evaluate new
active drugs and embolization agents to determine the
best criteria for treatment eﬃcacy, to assess which ther-
apeutic regimen is more appropriate (repeat treatment
according to a ﬁxed schedule or upon disease progres-
sion after initial response) and ﬁnally, to evaluate
whether the combination of TACE with other locore-
gional approaches such as radiofrequency ablation [12]
or with systemic drugs may further increase the impact
of TACE on overall survival.
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